Table 1 Correlation betweeen HMG-CoAR expression and clinicopathological parameters.
From: Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
HMG-CoAR intensity | 0 | 1 to 3 | |
|---|---|---|---|
n (%) | 111 (25.0) | 333 (75.0) | p value |
Age (years) | |||
Median | 65 | 64 | |
Range | 27 to 89 | 34 to 96 | 0.84 |
≤50 | 23 (20.7) | 51 (15.5) | |
>50 | 88 (79.3) | 279 (84.5) | 0.20 |
Tumour size (mm) | |||
Median | 20 | 15 | |
Range | 1 to 100 | 1 to 100 | <0.001 |
≤20 mm | 57 (51.4) | 217 (65.8) | |
>20 mm | 54 (48.6) | 113 (34.2) | 0.007 |
NHG | |||
I | 11 (9.9) | 97 (29.5) | |
II | 45 (40.5) | 133 (40.4) | |
III | 55 (49.5) | 99 (30.1) | <0.001 |
Node status | |||
Negative | 67 (65.7) | 179 (61.3) | |
Positive | 35 (34.3) | 113 (38.7) | 0.43 |
Unknown | 9 | 41 | |
ER status | |||
Negative | 22 (20.0) | 36 (10.9) | |
Positive | 88 (80.0) | 294 (89.1) | 0.01 |
Unknown | 1 | 3 | |
PR status | |||
Negative | 16 (14.8) | 45 (13.8) | |
Positive | 92 (85.2) | 281 (86.2) | 0.79 |
Unknown | 3 | 7 | |
n (%) | 111 (25.0) | 333 (75.0) | p-value |
Endocrine therapy (tamoxifen) | |||
No | 50 (55) | 147 (59) | |
Yes | 41 (45) | 103 (41) | |
Unknown | 20 | 83 | 0.53 |
Chemotherapy | |||
No | 81 (89) | 240 (95) | |
Yes | 10 (11) | 12 (5) | |
Unknown | 20 | 81 | 0.04 |
HER2 IHC | |||
0 | 77 (73.3) | 155 (48.9) | |
1 | 13 (12.4) | 89 (28.1) | |
2 | 6 (5.7) | 37 (11.7) | |
3 | 9 (8.6) | 36 (11.4) | <0.001 |
unknown | 6 | 16 | |
HER2 IHC | |||
0 to 2 | 96 (91) | 284 (89) | |
3 | 9 (9) | 36 (11) | 0.44 |
Unknown | 6 | 16 | |
Ki67 | |||
0 to 10% | 29 (27.6) | 122 (39.5) | |
11 to 25% | 35 (33.3) | 107 (34.6) | |
>25% | 39 (41.0) | 80 (25.9) | 0.02 |
Unknown | 8 | 24 |